Last $119.36 USD
Change Today +0.49 / 0.41%
Volume 481.8K
BDX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Open
$118.97
Previous Close
$118.87
Day High
$119.45
Day Low
$118.73
52 Week High
06/9/14 - $120.66
52 Week Low
09/3/13 - $96.73
Market Cap
23.1B
Average Volume 10 Days
551.0K
EPS TTM
$5.96
Shares Outstanding
193.2M
EX-Date
06/5/14
P/E TM
20.0x
Dividend
$2.18
Dividend Yield
1.78%
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices that are used in various healthcare settings. This segment’s products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles used in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transport of diagnostics specimens; and instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment’s products comprise integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Biosciences segment offers research and clinical tools that facilitate the study of cells and their components. This segment’s products include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

29,979 Employees
Last Reported Date: 11/27/13
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $930.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $144.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $690.0K
Executive Vice President
Total Annual Compensation: $605.7K
Senior Vice President and General Counsel
Total Annual Compensation: $516.3K
Compensation as of Fiscal Year 2013.

becton dickinson and co (BDX) Key Developments

BD Medical Signs Agreement for Installation of BD Cato Workflow Solution in University of Texas MD Anderson Cancer Center

BD Medical announced an agreement with The University of Texas MD Anderson Cancer Center for BD Cato, a system that enhances safety and workflow efficiency in medication preparation via gravimetric and barcoding technology. MD Anderson Cancer Center will be the first healthcare institution in the U.S. to implement the BD Cato System and will be incorporating the system into its outpatient infusion pharmacies, including community-based locations. BD Cato Workflow Solution provides an automated system that creates and shares data to reduce the possibility of human error, standardize practice, streamline workflow and increase efficiency from medication preparation to delivery in the pharmacy. The software detects potential medication errors and associated costs, automates documentation, and optimizes drug utilization to reduce drug waste. The system interfaces with Pharmacy IT systems to pull in physician orders and allow dose queue management within the preparation environment, thereby simultaneously improving safety and efficiency.

Becton, Dickinson and Company Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 10:40 AM

Becton, Dickinson and Company Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 10:40 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Vincent A. Forlenza, Chairman, Chief Executive Officer and President.

Becton, Dickinson and Company Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM

Becton, Dickinson and Company Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Linda Tharby, Worldwide Group President, Tom Polen, Worldwide Group President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $119.36 USD +0.49

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $56.60 USD +0.11
Astellas Pharma Inc ¥1,349 JPY +10.00
Boston Scientific Corp $13.29 USD +0.19
Stryker Corp $84.02 USD +0.34
Zimmer Holdings Inc $103.79 USD +0.12
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 25.2x
Price/Sales 2.8x
Price/Book 4.3x
Price/Cash Flow 24.3x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.